Inlyta
$394.00 – $1,974.00
Inlyta has been approved for use as a treatment for advanced renal cell carcinoma (RCC) in adults, either on its own or in conjunction with other medications
Inlyta (generic name: axitinib) is prescribed as a first-line treatment for adult patients diagnosed with an advanced stage kidney cancer known as renal cell carcinoma (RCC). It is used as monotherapy or in conjunction with either pembrolizumab or avelumab. Its primary mechanism of action is thought to inhibit angiogenesis (the formation of new blood vessels by tumors).
Brand Manufacturer: Order – August 26, 2024 @ 11:55 PM
Side Effects: The most common side effects of Inlyta are: Diarrhea Hypertension Fatigue Decreased appetite Nausea Hoarseness or changes in the pitch or quality of voice (dysphonia) Hand-Foot Syndrome (HFS) – tingling and tenderness, redness, swelling and pain on the palm of the hand and sole of the foot Weight loss Vomiting Abnormal physical weakness (asthenia) Constipation You should report any of these symptoms to the prescribing physician as soon as you notice them. There are also some rare but serious side effects, including: Hypertension. If severe and persistent despite use of antihypertensive therapy and dose reduction, your doctor may discontinue treatment. of Inlyta, Cardiac failure which may require permanent discontinuation of Inlyta Gastrointestinal perforation and fistula. Your doctor will monitor for symptoms of these periodically throughout treatment There may be signs of hypothyroidism, in which case your doctor may prescribe thyroid hormone replacement therapy Inlyta may affect wound healing Proteinuria , also called albuminuria, shows up as elevated protein in the urine. It is not a disease in and of itself but is a symptom of certain conditions that may be affecting the kidneys Inlyta can cause harm to a fetus. Patients who are engaging in sexual actcity should use effective contraception.
Indication: Inlyta (axitinib) is prescribed for adult patients who have been diagnosed with an advanced stage of renal cell carcinoma (RCC). It may be prescribed in combination with pembrolizumab for the first-line treatment of patients , or as a single agent when a prior systemic therapy failed. Renal cell cancer (also called kidney cancer or renal cell adenocarcinoma) is a disease in which malignant (cancer) cells have been found in the lining of tubules in the kidney. Some of the risk factors that may contribute to RCC include the following: Smoking Overuse of some pain medicines, including OTC meds Obesity Hypertension Genetics such as von Hippel-Lindau disease or hereditary papillary renal cell carcinoma. Signs of renal cell cancer may include: Blood in the urine A lump in the abdomen A persistent pain in the side Loss of appetite Weight loss for no known reason Anemia. Check with your doctor if you have any of these symptoms. RCC is usually diagnosed with a physical examination, followed if necessary by an ultrasound exam, blood chemistry studies, urinalysis, a CAT scan or MRI scan, and biopsy.
Reviews
Write a review
The product has no reviews
Leave your review
